Medical decision making with incomplete evidence - Choosing a platelet glycoprotein IIbIIIa receptor inhibitor for percutaneous coronary interventions

Medical Decision Making

Volumn 25, Issue 2, 2005, Pages 222-228

  Brophy, James M ^a   Joseph, Lawrence ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b NONE

Author keywords

Bayesian analysis; Decision making; Percutaneous coronary interventions; Platelet glycoprotein IIbIIIa receptor inhibitor

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ADJUVANT THERAPY; BAYES THEOREM; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROBABILITY; RANDOMIZATION; REVIEW; SYSTEMATIC REVIEW;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BAYES THEOREM; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; DECISION SUPPORT SYSTEMS, CLINICAL; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL ISCHEMIA; PLACEBOS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS;

EID: 15744393899     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X05275156     Document Type: Review

References (27)

1. American Heart Association. Angioplasty and Cardiac Revascularization Treatments and Statistics. Dallas (TX): www. americanheart.org (accessed Feb. 16, 2005).
2. Berger PB, Steinhubl S. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: A US perspective. Circulation. 2002;106:2284-7.
3. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-94.
4. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326:472.
5. Yazdanpanah Y, Sissoko D, Egger M, et al. Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. BMJ. 2004;328(7434):249-50.
6. Oxman AD, Sackett DL, Guyatt GH. Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group. JAMA. 1993;270:2093-5.
7. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. 1st ed. London: Chapman & Hall; 1995.
8. Carlin JB. Meta-analysis for 2 × 2 tables: a Bayesian approach. Stat Med. 1992;11(2):141-58.
9. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-61.
10. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-96.
11. The CAPTURE Study. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet. 1997;349:1429-35.
12. The EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
13. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734-41.
14. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-21.
15. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-66.
16. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-903.
17. The IMPACT-II investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997;349:1422-8.
18. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. 2000;356:2037-44.
19. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-53.
20. Eddy DM, Hasselblad V, Shachter R. Meta-analysis by the Confidence Profile Method: The Statistical Synthesis of Evidence. Boston: Academic Press; 1992.
21. PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-97.
22. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001;357:1915-24.
23. Lewsey JD, Leyland AH, Murray GD, Boddy FA. Using routine data to complement and enhance the results of randomised controlled trials. Health Technol Assess. 2000;4:1-55.
24. Stangl D, Berry D. Meta-analysis in Medicine and Health Policy. 1st ed. New York: Marcel Decker; 2000.
25. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-82.
26. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med. 1999;130:995-1004.
27. Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet. 2002;360:355-60.